Trials / Terminated
TerminatedNCT00265200
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
Bone Metabolic Markers, TRAP, and Zometa's Effect on Bone Metastasis Due to Lung Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- University of Louisville · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases due to lung cancer.
Detailed description
The purpose of this research study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases. The blood test will look for a protein, called TRAP, which is released into the blood stream by the breakdown of bone. This study will compare the TRAP blood test with other blood tests for bone destruction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | zoledronic acid | 3.0-4.0 mg by IV (in the vein), once a month for 6 months |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2009-08-01
- Completion
- 2010-12-01
- First posted
- 2005-12-14
- Last updated
- 2018-03-05
- Results posted
- 2017-04-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00265200. Inclusion in this directory is not an endorsement.